No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
HK Stock MarketDetailed Quotes
02216 BRONCUS-B
- 0.510
- -0.030-5.56%
Market Closed Apr 25 16:09 CST
268.87MMarket Cap-1225P/E (TTM)
0.540High0.510Low13.50KVolume0.540Open0.540Pre Close6.90KTurnover0.00%Turnover RatioLossP/E (Static)527.20MShares1.85052wk High0.19P/B268.87MFloat Cap0.46052wk Low--Dividend TTM527.20MShs Float18.000Historical High--Dividend LFY5.56%Amplitude0.460Historical Low0.511Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Kunbo Medical-B (02216) appoints Xu Hong as chairman
Kunbo Medical-B (02216) announced that since April 19, 2024, Zhao Yiwei has resigned as a non-executive director,...
Kunbo Healthcare (02216.HK) Announces 2023 Annual Results
The development of lung disease treatment products continues to lead, and product sales are steadily advancing in Hangzhou, March 28, 2024/PRNewswire/ -- On March 28, 2024, Kunbo Medical (02216.HK), a leader in precise interventional diagnosis and treatment of lung diseases in China, announced its annual results for the year ended December 31, 2023. During the reporting period, the company achieved product sales revenue of US$12.41 million, an increase of 32% over the previous year. Among them, the total sales revenue of products in mainland China was US$8.62 million, up 48% year on year. In 2023, the company will have a firm industrial layout around “navigation-diagnosis-treatment”, and it will expand
BRONCUS-B: (I) ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023; AND (II) PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
Kunbo Medical-B (02216.HK) will hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Kunbo Medical-B (02216.HK) announced that the company will hold a board meeting on March 28, 2024 to approve the annual results of the company and its subsidiaries for the year ended December 31, 2023.
BRONCUS-B: DATE OF BOARD MEETING
Kunbo Medical-B Announces Zi Zhenjun's Resignation as Non-Executive Director
Kunbo Medical-B (02216) announced that Zi Zhenjun has resigned as a non-executive director due to his intention to invest more time in other personal matters, effective March 1, 2024.
Comments
$BRONCUS-B(02216.HK$ Kunbo Medical's Hong Kong stock market breaks, the first listing closes down 19.79%
Kunbo Medical, an interventional medical device company, was listed on the Hong Kong Stock Exchange on Friday with an issue price of HK$18.7 and a net fund-raising of HK$1.552 billion. The first listing closed down 19.79%; excluding handling fees, the first-hand book value was HK$1,850. The cornerstone investors of Kunbo Medical include Snow Lake Capital, Qifeng Capital, etc.
Kunbo Medical, an interventional medical device company, was listed on the Hong Kong Stock Exchange on Friday with an issue price of HK$18.7 and a net fund-raising of HK$1.552 billion. The first listing closed down 19.79%; excluding handling fees, the first-hand book value was HK$1,850. The cornerstone investors of Kunbo Medical include Snow Lake Capital, Qifeng Capital, etc.
1
1
$BRONCUS-B(02216.HK$ is the leader of a small segment of the track. This is its main premium space. The "outbreak" of $HELENS(09869.HK$ was once seen by the market as a sign of a new recovery. I think we can pay attention to it. If you are more cautious, you can look at the dark market and make a profit if it rises. Generally, the performance on the first day will not be too bad.
1
Read more
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg
102768097 : how to do?